Across TCGA pan-cancer cohorts, ELSPBP1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ELSPBP1 data layer compared with 15 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ELSPBP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ELSPBP1 expression acts as an unfavorable survival marker.
UCEC, LIHC, and SARC are the cancer types where ELSPBP1 Mutation most reproducibly stratifies survival.